EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY-NC 4.0

Efficacy of Modern Therapies for Heart Failure with Reduced Ejection Fraction in Specific Population Subgroups: A Systematic Review and Network Meta-Analysis

Carlo Lavalle, Marco Valerio Mariani, Paolo Severino, Marta Palombi, Sara Trivigno, Andrea D'Amato, Giacomo Silvetti, Nicola Pierucci, Luca Di Lullo, Cristina Chimenti, Francesco Summaria, Claudio Ronco und 3 weitere

Cardiorenal Medicine · 16.09.2024 · 14 (1) · 570-580

DOI: 10.1159/000541393 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cardiorenal Medicine, online erschienen am 16.09.2024. Verfasst von Carlo Lavalle und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical, Internal, Anesthesiologist and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Aminobutyrates, Heart Failure, Stroke Volume. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The efficacy and safety of emerging therapies for heart failure with reduced ejection fraction (HFrEF) have never been compared in specific subgroups of patients.

Methods

PubMed, Cochrane Registry, Web of Science, Scopus, and EMBASE libraries were used to extract data. We used the following keywords: (heart failure with reduced ejection fraction OR HFrEF) AND (treatment OR therapy) OR (cardiovascular death) OR (hospitalization for heart failure). We compared randomized clinical trials for HFrEF emerging therapies focusing on the elderly (patients >65 years old and >75 years old), chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR) < 60 mL/min), patients with diabetes mellitus (DM), coronary heart disease (CAD), New York Heart Association (NYHA) class III/IV, women, patients on sacubitril/valsartan (S/V). The primary outcome was the efficacy composite endpoint of cardiovascular death (CVD) and HF hospitalization (HFH).

Results

S/V significantly reduced the primary outcome in patients >65 years old (RR: 0.80; 95% CI: 0.68–0.94) and with CKD (RR: 0.79; 95% CI: 0.69–0.90); dapagliflozin in patients >65 (RR: 0.72; 95% CI: 0.60–0.86) and >75 years old (RR: 0.68; 95% CI: 0.53–0.87), in those with CKD (RR: 0.72; 95% CI: 0.59–0.88), DM (RR: 0.75; 95% CI: 0.63–0.89), and CAD (RR: 0.77; 95% CI: 0.65–0.92); empagliflozin in patients >65 years old (RR: 0.78; 95% CI: 0.66–0.93), those with DM (RR: 0.72; 95% CI: 0.60–0.86), CAD (RR: 0.82; 95% CI: 0.68–0.99), women (RR: 0.59; 95% CI: 0.44–0.79), and in patients on S/V (RR: 0.64; 95% CI: 0.45–0.91); vericiguat in patients with CKD (RR: 0.84; 95% CI: 0.73–0.97) and NYHA class III/IV (RR: 0.87; 95% CI: 0.77–0.98); omecamtiv mecarbil in patients with CAD (RR: 0.90; 95% CI: 0.82–0.99) and NYHA III/IV (RR: 0.88; 95% CI: 0.80–0.97).

Conclusion

Emerging HFrEF therapies show a clinical benefit with the reduction of the primary composite endpoint of CVD and HFH, with each drug being more effective in specific patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminobutyratesHeart FailureStroke VolumeAgedFemaleHumansAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsGlomerular Filtration RateHospitalizationRandomized Controlled Trials as TopicRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsTreatment OutcomeValsartanMale

Stichwörter der Autor:innen

Cardiovascular deathHeart failure with reduced ejection fractionHospitalization for heart failureMeta-analysisTreatment

Substanzen

AminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationSodium-Glucose Transporter 2 InhibitorsValsartan

Autor:innen und Institutionen

  • Department of Clinical, Internal, Anesthesiologist and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Department of Nephrology and Dialysis, Azienda USL Roma 6, Rome, Italy.
  • Department of Cardiology, S. Eugenio Hospital, Rome, Italy.
  • Department of Nephrology and Dialysis, International Renal Research Institute, S. Bortolo Hospital, Vicenza, Italy.

Zitieren

APA

Lavalle, C., Mariani, M. V., Severino, P., Palombi, M., Trivigno, S., D'Amato, A., Silvetti, G., Pierucci, N., Di Lullo, L., Chimenti, C., Summaria, F., Ronco, C., Badagliacca, R., Miraldi, F., & Vizza, C. D. (2024). Efficacy of Modern Therapies for Heart Failure with Reduced Ejection Fraction in Specific Population Subgroups: A Systematic Review and Network Meta-Analysis. Cardiorenal Medicine, 14(1), 570-580. https://doi.org/10.1159/000541393

Vancouver

Lavalle C, Mariani MV, Severino P, Palombi M, Trivigno S, D'Amato A, et al. Efficacy of Modern Therapies for Heart Failure with Reduced Ejection Fraction in Specific Population Subgroups: A Systematic Review and Network Meta-Analysis. Cardiorenal Medicine. 2024;14(1):570-580. doi:10.1159/000541393

BibTeX
@article{Lavalle2024,
  author = {Lavalle, Carlo and Mariani, Marco Valerio and Severino, Paolo and Palombi, Marta and Trivigno, Sara and D'Amato, Andrea and Silvetti, Giacomo and Pierucci, Nicola and Di Lullo, Luca and Chimenti, Cristina and Summaria, Francesco and Ronco, Claudio and Badagliacca, Roberto and Miraldi, Fabio and Vizza, Carmine Dario},
  title = {Efficacy of Modern Therapies for Heart Failure with Reduced Ejection Fraction in Specific Population Subgroups: A Systematic Review and Network Meta-Analysis},
  journal = {Cardiorenal Medicine},
  year = {2024},
  volume = {14},
  number = {1},
  pages = {570--580},
  doi = {10.1159/000541393}
}
Kostenlos starten →